Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 26Leukemia, Myeloid, Acute 24Recurrence 12Sarcoma 7Lymphoma, Large B-Cell, Diffuse 6Neoplasm Metastasis 5Neurofibrosarcoma 4Neoplasms, Plasma Cell 4Lymphoma 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Thymoma 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Leukemia 2Congenital Abnormalities 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Wilms Tumor 1

Interventions

selinexor 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Extensive Stage Small Cell Lung Cancer (ES-SCLC) × selinexor × Clear all
NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
30 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡